{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-066915","form_type":"8-K","ticker":"TMCI","cik":"0001630627","company_name":"TREACE MEDICAL CONCEPTS, INC.","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.129004+00:00","generated_at":"2026-05-22T04:37:59.811817+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Treace Q1 revenue $52.6M (+3% YoY); net loss improves to $(15.9)M; reaffirms FY2025 guidance","bullets":["Revenue $52.6M, up 3% from $51.1M; adjusted for one less selling day, growth 4.5%.","Net loss $(15.9)M ($(0.25)/share) vs $(18.7)M ($(0.30)/share) in Q1 2024, improved 15%.","Adjusted EBITDA $(3.8)M, a 53% improvement from $(8.3)M in prior-year quarter.","Reaffirms FY2025 revenue guidance $224-230M (7-10% growth) and breakeven adjusted EBITDA.","Launched three new bunion systems (Nanoplasty, Percuplasty 3D MIS, SpeedMTP MTP Fusion)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-066915","json":"https://secwatch.observer/filing/0000950170-25-066915.json","markdown":"https://secwatch.observer/filing/0000950170-25-066915.md","text":"https://secwatch.observer/filing/0000950170-25-066915.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1630627/000095017025066915/0000950170-25-066915-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1630627/000095017025066915/tmci-20250508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T04:37:59.811817+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}